NASDAQ:DRNA Dicerna Pharmaceuticals (DRNA) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free DRNA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$38.22▼$38.2250-Day Range$37.81▼$38.2552-Week Range$19.06▼$40.14VolumeN/AAverage Volume1.34 million shsMarket Capitalization$2.99 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Dicerna Pharmaceuticals alerts: Email Address Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Dicerna Pharmaceuticals Stock (NASDAQ:DRNA)Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.Read More Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 DRNA Stock News HeadlinesMay 25, 2023 | fool.comArrowhead Pharmaceuticals (NASDAQ: ARWR)February 16, 2023 | thestreet.com'Mad Money' Lightning Round: I'm Staying Away From Five BelowApril 27, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…February 7, 2023 | benzinga.comBiondVax Pharmaceuticals Stock (NASDAQ:BVXV), Quotes and News SummaryJanuary 26, 2023 | marketwatch.comMyc Proto-Oncogene Protein Market 2023 Statistics, Industry Share, Latest Trends, Growth Drivers, Size Estimate and Forecast till 2028January 19, 2023 | finance.yahoo.comWe Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business GrowthJanuary 14, 2022 | ca.finance.yahoo.comDRNA Jul 2022 40.000 call(CONTRJanuary 14, 2022 | ca.finance.yahoo.comDRNA Jan 2022 22.500 callApril 27, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…December 28, 2021 | finance.yahoo.comNovo Nordisk Announces Completion of Dicerna Pharmaceuticals AcquisitionNovember 19, 2021 | prnewswire.comDICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNANovember 19, 2021 | finance.yahoo.comSHAREHOLDER ALERT: WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc.November 18, 2021 | finance.yahoo.comDICERNA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of DRNA and Encourages Investors to Contact the FirmNovember 18, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Dicerna Pharmaceuticals, Inc. to Novo NordiskNovember 18, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Dicerna Pharmaceuticals, Inc.November 18, 2021 | barrons.comDicerna Stock Skyrockets as Novo Nordisk to Buy Research Partner for $3.3 BillionNovember 18, 2021 | finance.yahoo.comUPDATE 3-Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billionNovember 12, 2021 | finance.yahoo.comDicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021November 12, 2021 | finance.yahoo.comDicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With LillyNovember 10, 2021 | benzinga.comDicerna Pharmaceuticals's Return On Capital Employed OverviewNovember 9, 2021 | sfgate.comDicerna Pharmaceuticals: Q3 Earnings SnapshotNovember 9, 2021 | finance.yahoo.comDicerna Announces Third Quarter 2021 Financial Results and Provides a Business UpdateNovember 4, 2021 | finance.yahoo.comDicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021October 18, 2021 | finance.yahoo.comHedge Fund Sentiment Is Stagnant On Dicerna Pharmaceuticals Inc (DRNA)October 15, 2021 | finance.yahoo.comDicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021October 14, 2021 | benzinga.comDicerna Highlights Will Give Poster Presentations At American Association For Study Of Liver Nov. 12-15, 2021October 14, 2021 | finance.yahoo.comDicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in NovemberSee More Headlines Receive DRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dicerna Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:DRNA CUSIPN/A CIK1399529 Webwww.dicerna.com Phone(617) 621-8097Fax617-612-6298Employees302Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,750,000.00 Net Margins-64.53% Pretax Margin-63.82% Return on Equity-103.08% Return on Assets-16.58% Debt Debt-to-Equity RatioN/A Current Ratio2.46 Quick Ratio2.46 Sales & Book Value Annual Sales$164.31 million Price / Sales18.17 Cash FlowN/A Price / Cash FlowN/A Book Value$1.84 per share Price / Book20.77Miscellaneous Outstanding Shares78,129,000Free Float70,160,000Market Cap$2.99 billion OptionableOptionable Beta0.80 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDouglas M. FambroughPresident, Chief Executive Officer & DirectorJames B. WeissmanChief Operating Officer & Executive Vice PresidentDouglas W. PagánChief Financial OfficerBob D. BrownChief Scientific OfficerShreeram AradhyeChief Medical Officer & Executive Vice PresidentKey CompetitorsArrowhead PharmaceuticalsNASDAQ:ARWRIDEAYA BiosciencesNASDAQ:IDYACrinetics PharmaceuticalsNASDAQ:CRNXXenon PharmaceuticalsNASDAQ:XENEBausch Health CompaniesNYSE:BHCView All Competitors DRNA Stock Analysis - Frequently Asked Questions How were Dicerna Pharmaceuticals' earnings last quarter? Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.41) by $0.19. The biopharmaceutical company had revenue of $62.95 million for the quarter, compared to analyst estimates of $58.83 million. Dicerna Pharmaceuticals had a negative trailing twelve-month return on equity of 103.08% and a negative net margin of 64.53%. During the same period in the prior year, the company earned ($0.29) earnings per share. What is Douglas M. Fambrough, Ph.D.'s approval rating as Dicerna Pharmaceuticals' CEO? 35 employees have rated Dicerna Pharmaceuticals Chief Executive Officer Douglas M. Fambrough, Ph.D. on Glassdoor.com. Douglas M. Fambrough, Ph.D. has an approval rating of 99% among the company's employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Dicerna Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Gilead Sciences (GILD), Pfizer (PFE) and Advanced Micro Devices (AMD). This page (NASDAQ:DRNA) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dicerna Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
